Wound Management News

A recent case series elucidated several clinical factors and treatment options for erosive pustular disorder.

Recent 12-month data from a phase 2b trial demonstrated that Genocea Biosciences’ lead GEN-003 vaccine regimen reduced the median rate of genital lesions by nearly 50% compared with placebo among patients with herpes simplex virus-2.

Study results reporting that nail findings distinguished patients with psoriatic arthritis from those with psoriasis without arthritis was among the top read articles in July on Healio.com/Dermatology.

Paratek Pharmaceuticals recently announced that its investigational antibiotic omadacycline — a once-daily, oral treatment for acute bacterial skin and skin structure infections, or ABSSSIs — met all primary and secondary endpoints specified by the FDA and European Medicines Agency in a recent phase 3 study that compared the safety and efficacy of the drug with twice-daily Zyvox.

Bullous pemphigoid demonstrated some association with hematologic malignancy despite showing no association with overall malignancy.

Another study has shown the clinical benefit of adding antibiotic therapy to incision and drainage treatment for uncomplicated skin abscesses.

The FDA’s approval of Baxdela for treating acute bacterial skin and skin structure infections was among the top read articles of the past week on Healio.com/Dermatology.

The FDA announced today that it has approved Baxdela to treat acute bacterial skin and skin structure infections.

Case report study results that Keytruda therapy was associated with eruptive keratoacanthomas in three patients with metastatic squamous cell carcinoma or metastatic melanoma was among recent developments reported on Healio.com/Dermatology.

United States District Judge Kathleen M. Williams for the Southern District of Florida issued a consent decree of permanent injunction against Stratus Pharmaceuticals and Sonar Products, as well as the companies’ officers, Alberto Hoyo and Juan Carlos Billoch, for routinely shipping unapproved, misbranded and substandard or adulterated drugs in interstate commerce, according to a press release issued by the FDA.